$MDXG

MIMEDX GROUP, INC.

MIMEDX develops and sells products used by clinicians to help treat chronic and other hard-to-heal wounds, burns, and surgical conditions. Its portfolio includes human placental tissue allografts such as EPIFIX, EPICORD and EPIEFFECT, processed using its PURION process, and products for surgical applications such as AMNIOEFFECT and AXIOFILL. MIMEDX also offers HELIOGEN, a bovine collagen matrix, and distributes wound-care products including RegenKit-Wound Gel, NovaForm Wound Matrix, G4Derm Plus and Hydrelix Collagen Matrix. MIMEDX sells through its direct sales team, independent sales agents and distributors. Customers include hospitals, wound care clinics, physician offices, ambulatory surgery centers and federal healthcare facilities. Distributors buy products at wholesale prices and resell them to providers and end users. MIMEDX is headquartered in Marietta, Georgia, where its manufacturing facilities process donated birth tissue.

0
1
1

No SEC Form 4 filings for $MDXG in the last 30 days.

See all $MDXG insider activity →
Med

MiMedx Group Bets on Surgery Growth and Sanara Deal as Wound Care Struggles

MiMedx Group (MDXG) is awaiting FTC approval for a deal and faces challenges due to Medicare reimbursement changes. CEO Rice noted a 3Q inflection point with improving margins and $40M in surgical revenue. The company also reported positive data on AMNIOFIX grafts and a $25M settlement related to AXIOFILL.

MiMedx Group Earnings Call: Surgical Growth Meets Wound Care Pressure

MiMedx Group reported Q3 earnings with mixed results. Surgical revenue grew 9% YoY to $40M, but Wound Care revenue dropped 71% due to Medicare reimbursement changes. Adjusted EBITDA turned positive at $2M, and the company has a strong cash position. The Sanara acquisition, if completed, could expand its market reach. Management expects double-digit growth and cost synergies post-acquisition. Wound Care stabilization remains uncertain.

MDXG sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MDXG (MIMEDX GROUP, INC.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.

Recent MDXG coverage spans earnings, mergers & acquisitions and financial news.

What's driving MDXG

  • The acquisition could expand MDXG's surgical portfolio, offsetting wound‑care margin pressure, but integration risk and reimbursement challenges remain.

    finance.yahoo.com · Nov 16, 2026

  • Earnings miss and regulatory setbacks likely weigh on the stock.

    tipranks.com · Nov 14, 2026

  • MiMedx Group's (MDXG) average price target was reduced from $7.4 to $7.2 by 5 analysts, with a range of $6 to $8. This implies 82% upside from the Oct. 28 closing price. The consensus rating remains 'Buy' across all analysts.

    tradingview.com · Oct 29, 2026

  • Mixed impact: settlement and strong surgical growth support upside, while FTC second request may pressure the stock.

    finance.yahoo.com · Oct 29, 2026

  • The cash inflow improves near‑term liquidity and may lift the stock modestly.

    investing.com · Oct 28, 2026

AlphAI scores every news story that mentions MDXG with an AI model for sentiment and relevance, and aggregates insider trades from MIMEDX GROUP, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MDXG

Score

MiMedx Group Earnings Call: Surgical Growth Meets Wound Care Pressure

MiMedx Group reported Q3 earnings with mixed results. Surgical revenue grew 9% YoY to $40M, but Wound Care revenue dropped 71% due to Medicare reimbursement changes. Adjusted EBITDA turned positive at $2M, and the company has a strong cash position. The Sanara acquisition, if completed, could expand its market reach. Management expects double-digit growth and cost synergies post-acquisition. Wound Care stabilization remains uncertain.

MiMedx (MDXG) Q3 2026 Earnings Call Transcript

MiMedx (MDXG) reported Q3 2026 net sales of $62M, with Surgical revenue up 9% YoY and Wound Care Center volume up 7% sequentially. The company expects to complete the Sanara MedTech acquisition, pending FTC approval, aiming for $400M in combined revenue and 20% adjusted EBITDA margin. MiMedx also won a court ruling against the FDA's classification of AXIOFILL and reached a $25M settlement in a patent infringement case.

$MDXGMedEarnings

MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers…

MIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Results of Operations and Financial Condition. MIMEDX Announces Third Quarter 2026 Operating & Financial Results Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year Obtained Favorable Federal Court Ruling in AXIOFILL®

MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months

The FTC issued a Second Request for more information on MiMedx's (MDXG) acquisition of Sanara (SMTI), delaying the merger beyond the year-end target. SMTI shares fell 5.5%, dropping below their 50-day moving average, while MDXG shares declined 2.8%. The deal, valued at $35 per share, aims to create a larger regenerative medicine company with $400M revenue expected in FY2027.

$MDXGMedM&A· acquirer · definitive

MiMedx Group, Inc., a Florida corporation, entered into an Agreement and Plan of Merger with Sanara MedTech Inc., a Texas corporation, and Mustang Merger…

MIMEDX GROUP, INC. (MDXG) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously announced, MiMedx Group, Inc., a Florida corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanara MedTech Inc., a Texas corporation (“Sanara”), and Mustang Merger Sub, Inc., a wholly-owned

Related tickers